Rasmussen encephalitis: Response to early immunotherapy in a case of immune-mediated encephalitis

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F15%3A10322603" target="_blank" >RIV/00216208:11130/15:10322603 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064203:_____/15:10322603

Výsledek na webu

<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4335812/" target="_blank" >http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4335812/</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1212/NXI.0000000000000069" target="_blank" >10.1212/NXI.0000000000000069</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Rasmussen encephalitis: Response to early immunotherapy in a case of immune-mediated encephalitis

Popis výsledku v původním jazyce

Rasmussen encephalitis (RE) is a severe immune-mediated neurologic disease characterized by unihemispheric inflammation, progressive neurologic deficits, and intractable focal epilepsy. Functional hemispherectomy is considered to be the only effective intervention for this devastating disease.Reports on immunotherapy use in RE, including steroids, IV immunoglobulin, and tacrolimus, have been published. These therapies may lead to ""arrest"" of the disease in patients with pharmacoresistant epilepsy in whom motor function is not impaired enough to be offered a functional hemispherectomy. Information regarding the effect of early and aggressive immunotherapy on cognitive function, MRI disease activity, and seizure control in this population is limited. Here we present a case of a child satisfying 2005 Bien diagnostic criteria for RE in whom disease control and motor and cognitive preservation was achieved using early aggressive immunotherapy.

Název v anglickém jazyce

Rasmussen encephalitis: Response to early immunotherapy in a case of immune-mediated encephalitis

Popis výsledku anglicky

Rasmussen encephalitis (RE) is a severe immune-mediated neurologic disease characterized by unihemispheric inflammation, progressive neurologic deficits, and intractable focal epilepsy. Functional hemispherectomy is considered to be the only effective intervention for this devastating disease.Reports on immunotherapy use in RE, including steroids, IV immunoglobulin, and tacrolimus, have been published. These therapies may lead to ""arrest"" of the disease in patients with pharmacoresistant epilepsy in whom motor function is not impaired enough to be offered a functional hemispherectomy. Information regarding the effect of early and aggressive immunotherapy on cognitive function, MRI disease activity, and seizure control in this population is limited. Here we present a case of a child satisfying 2005 Bien diagnostic criteria for RE in whom disease control and motor and cognitive preservation was achieved using early aggressive immunotherapy.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FH - Neurologie, neurochirurgie, neurovědy

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Neurology: Neuroimmunology &amp; Neuroinflammation [online]

ISSN

2332-7812

e-ISSN

—

Svazek periodika

2015

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

4

Strana od-do

1-4

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—